For a person experiencing aHUS (atypical hemolytic uremic syndrome / C-TMA/cTMA) onset who arrives at a hospital, acute stabilization (often with plasma exchange/PEX) is usually provided regardless of coverage status in most countries, as it is a medical emergency. Long-term treatment with expensive complement inhibitors (eculizumab/Soliris or ravulizumab/Ultomiris, costing hundreds of thousands USD per year) depends heavily on insurance, public reimbursement, or assistance programs.
“Covered” here means the person has local public or private health insurance/residency-based coverage. “Uncovered” means uninsured, self-pay, or non-resident without applicable insurance. Information is based on 2024–2026 policies; exact outcomes vary by hospital, residency status, and individual case (e.g., prior authorization, genetic confirmation).
Finishing the title:
…how will they be treated and who will pay for it in:
| Country | Covered patient | Uncovered |
| USA | Commercial/Medicare/Medicaid insurance typically covers after prior authorization. Alexion OneSource copay program often reduces out-of-pocket to $0 for eligible commercial plans. Some co-pay. | Alexion OneSource Patient Assistance Program provides free drug for eligible US residents (income-based). Additional help via NORD, Good Days, or hospital charity. Non-residents usually pay full price or use travel insurance. |
.
| UK | UK NHS fully covers eculizumab and ravulizumab (NICE-approved; managed via National aHUS Service). Free at point of care for eligible residents. | Universal system — most residents are covered. Non-residents/foreigners typically pay privately or via travel insurance; rare charitable access. |
| France | Sécurité Sociale + HAS reimbursement: fully or largely covered as an orphan drug for confirmed aHUS. | Rare for residents (social aid available). Non-residents pay out-of-pocket or via travel insurance; compassionate use possible in some cases. |
| Germany | Statutory health insurance (G-BA assessed and reimbursed). Additional benefit recognized for complement inhibitors. | Social welfare or hospital social funds may help. Manufacturer compassionate programs or out-of-pocket (rare for residents). |
| Egypt | Public hospitals: limited/no routine coverage for complement inhibitors (PEX often used instead). Private insurance: variable reimbursement. | Almost entirely out-of-pocket (very high cost; drug not widely marketed). PEX is the practical alternative in public care. |
| UAE | Government coverage for citizens; private insurance for expats often covers in private hospitals (subject to policy). | Full out-of-pocket in private hospitals (estimates: $50,000–$100,000+ USD per course). Public hospitals may use PEX; limited drug access. |
| India | National Program for Rare Diseases (NPRD) provides government funding for eligible patients (eculizumab approved 2025). Private insurance: rare coverage. | Out-of-pocket (expensive; supply improved post-approval). PEX is common alternative. Some state/government hospital aid or crowdfunding. |
| Japan | National Health Insurance covers approved drugs (eculizumab since 2015). High-cost medical expense subsidy system caps patient costs. | High-cost subsidy still applies; out-of-pocket capped for residents. Non-residents pay full price or via insurance. |
| Australia | Pharmaceutical Benefits Scheme (PBS) subsidizes eculizumab and ravulizumab (Section 100 listing). Low or no copay for most. | Full price (very expensive) unless safety-net provisions or charitable aid apply. Non-residents rely on travel insurance. |
| Argentina | Private insurance: variable coverage. Public system: limited access (shortages reported). | Mostly out-of-pocket; limited Soliris availability. PEX is frequently used due to access barriers. |
| Brazil | Private insurance: may cover. Public (SUS/CONITEC): limited reimbursement (e.g., advised against Ultomiris in 2025; Soliris access inconsistent). | Out-of-pocket with frequent shortages. PEX is the main option in public hospitals. |
| Nepal | Acute care (plasma exchange sessions, dialysis) may receive partial reimbursement or subsidy under the insurance scheme. However, the patient still cannot access eculizumab or ravulizumab through insurance. Any imported drug would be fully out-of-pocket | The patient pays the full cost for plasma exchange, dialysis, and hospital stay (often significant in private facilities). Foreign/non-resident patients are usually required to provide substantial upfront payment guarantees. Ongoing care relies entirely on family resources. |
There is disparity in whether any treatment will cost the ill person anything.
There will also be disparity in how much bureaucratic effort an ill person will have to make to avoid it costing them nothing or not very much.
There are likely disparities in outcomes too
. The uncovered person is more likely to die or end up on chronic dialysis .
Fortunately the latter may be covered but may be unaffordable in the long run leading eventually to death.
Written with the help from the internet, so happy to be corrected.
Article 791
